DeltaDOT

About DeltaDOT

DeltaDOT is a biotechnology firm that originated as a spin-out from Imperial College London in 2000. The company was co-founded by Dr. John Hassard and Dr. Stuart Hassard. John Hassard's background is in the High Energy Physics Group at Imperial's Department of Physics, with prior research fellowships at Harvard and Cornell University. Stuart Hassard brought molecular biology expertise to the venture, with a Ph.D. from the University of Essex and post-doctoral work at the USDA and the University of Cambridge.

The firm's core business revolves around High-Performance Capillary Electrophoresis (HPCE), an advanced analytical technique. DeltaDOT designs, manufactures, and globally markets its own line of HPCE instruments that utilize a proprietary imaging and analysis technology known as Label-Free Intrinsic Imaging (LFII®). This technology is designed to enable the detection, separation, and analysis of a wide range of unlabeled biomolecules, including proteins, nucleic acids, and viruses. By avoiding the need for molecular labels, the system aims to improve data quantification, reduce operating costs, and decrease throughput times.

DeltaDOT's business model is twofold. The company generates revenue through the direct sale of its HPCE instruments, such as the 'Peregrine' Protein/Nucleic Acid analysis system and the 'Merlin' DNA sequencer, to a global market. In parallel, it leverages its in-house scientific expertise and instrumentation to offer analytical services and contract research to clients in academia and various industries. The company operates within the life sciences research, drug testing, diagnostics, and biopharmaceutical manufacturing sectors. Its client base includes research and production laboratories, contract labs, and organizations within the pharmaceutical industry.

Over its history, DeltaDOT has secured significant financing, including a £2.3 million round in 2005 and another $10.5 million in 2006, with total funding reaching $22.3M from investors like Imperial Innovations Ltd, NPI Ventures, and Fleming Family & Partners. The company is headquartered in the London Bioscience Innovation Centre.